The diagnostic value of soluble urokinase plasminogen activator receptor compared with C-reactive protein and procalcitonin in children with febrile neutropenia

References

• Haeusler GM, Carlesse F, Phillips RS. An updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment of fever during neutropenia in children with cancer. Pediatr Infect Dis J. 2013;32:390–396.
   Web of Science ®Google Scholar
• Thuno M, Macho B, Eugen-Oslen J. suPAR: the molecular crystal ball. Dis Markers. 2009;27:157–172.
   PubMed Web of Science ®Google Scholar
• Ostergaard C, Benfield T, Lundgren JD, et al. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis. 2004;36:14–19.
   PubMedGoogle Scholar
• Huttunen R1, Syrjänen J, Vuento R, et al. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med. 2011;270:32–40.
   PubMed Web of Science ®Google Scholar
• Ostrowski SR, Katzenstein TL, Piironen T, Gerstoft J, Pedersen BK, Ullum H. Soluble urokinase receptor levels in plasma during 5 sources of highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004;35:337–342.
   PubMed Web of Science ®Google Scholar
• Perch M, Kofoed P, Fischer TK, et al. Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection. Parasite Immunol. 2004;26:207–211.
   PubMed Web of Science ®Google Scholar
• Garcia-Monco JC, Coleman JL, Benach JL. Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases. J Neuroimmunol. 2002;129:216–222.
   PubMed Web of Science ®Google Scholar
• 8-Chounta A, Ellinas C, Tzanetakou V, et al. Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma. Liver Int. 2015;35:601–607.
   PubMed Web of Science ®Google Scholar
• Wach S, Al-Janabi O, Weigelt K, et al. The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer. Int J Cancer. 2015;137:1406–1416.
   PubMed Web of Science ®Google Scholar
• Fidan E, Mentese A, Ozdemir F, et al. Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer. Med Oncol. 2013;30:540.
   PubMed Web of Science ®Google Scholar
• Langkilde A, Hansen TW, Ladelund S, et al. Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals. Cancer Epidemiol Biomarkers Prev. 2011;20:609–618.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:56--93.
   Google Scholar
• National Institute for Health and Care Excellence. Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients. http://publications.nice.org.uk/neutropenic-sepsis-prevention-and-management-of-neutropenic-sepsis-in-cancer-patients-cg151. Published 2012. Accessed June 19, 2013.
   Google Scholar
• Mizukami IF, Faulkner NE, Gyetko MR, et al. Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood. 1995;86:203–211.
   PubMed Web of Science ®Google Scholar
• Koch A, Voigt S, Kruschinski C, et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care. 2011;15:63--77.
   Google Scholar
• Kofoed K, Eugen-Olsen J, Petersen J, et al. Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Clin Microbiol Infect Dis. 2008;27:375–383.
   PubMed Web of Science ®Google Scholar
• Miyake H, Hara I, Yamanaka K, et al. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate. 1999;39:123–129.
   PubMed Web of Science ®Google Scholar
• Pappot H, Høyer-Hansen G, Rønne E, et al. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer. 1997;33:867–872.
   PubMed Web of Science ®Google Scholar
• Sidenius N, Sier CF, Ullum H, et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood. 2000;15;96:4091–4095.
   Google Scholar
• Kofoed K, Andersen O, Kronborg G, et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care. 2007;11:38.
   Web of Science ®Google Scholar
• Backes Y, van der Sluijs KF, Mackie DP, et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med. 2012;38:1418–1428.
   PubMed Web of Science ®Google Scholar
• Gustafson A, Ljunggren L, Bodelsson M, et al. The Prognostic value of suPAR compared to other inflammatory markers in patients with severe sepsis. Biomarker Insights. 2012;7:39–44.
   PubMedGoogle Scholar
• Phillips RS, Wade R, Lehrnbecher T, et al. Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people withcancer. BMC Med. 2012;18:6.
   Google Scholar
• Kim DY, Lee YS, Ahn S, et al. The usefulness of procalcitonin and C-reactive protein as early diagnostic markers of bacteremia in cancer patients with febrile neutropenia. Cancer Res Treat. 2011;43:176–180.
   PubMedGoogle Scholar
• Miedema KG, de Bont ES, Elferink RF, et al. The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer. 2011;19:1593–1600.
   PubMed Web of Science ®Google Scholar
• Kaya S, Köksal İ, Menteşe A, et al. The significance of serum urokinase plasminogen receptor (suPAR) in the diagnosis and follow up febrile neutropenic patients with hematologic malignancies. Int J Infect Dis. 2013;17:1056–1059.
   Web of Science ®Google Scholar
• Ostrowski SR, Ullum H, Goka BQ, et al. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis. 2005;15;191:1331–1341.
   Google Scholar
• Kolho KL, Valtonen E, Rintamaki H, et al. Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease. Scand J Gastroenterol. 2012;47:951–955.
   PubMed Web of Science ®Google Scholar
• Wittenhagen P, Andersen JB, Hansen A, et al. Plasma soluble urokinase plasminogen activator receptor in children with urinary tract infection. Biomarker Insights. 2011:6:79–82.
   PubMedGoogle Scholar
• Wrotek A, Jackowska T, Pawlik K. Soluble urokinase plasminogen activator receptor: an indicator of pneumonia severity in children. Adv Exp Med Biol. 2015;835:1–7.
   PubMed Web of Science ®Google Scholar